My mom died of Ovarian cancer over 20 years ago. By the time it was detected, she was already at stage 3 or 4. It's sad that in 2021 there is still no effective way to detect this cancer earlier and therefore increase the likelihood of survival.
I have be dealing with Cancer disease for the past years until i got review online about Dr.Auchi on RUclips Channel people testifies how they got cured with his herbal medicine, I order the treatment and after taking it for few weeks i totally got cured permanently ruclips.net/channel/UCz9T50vxGu2pQMiJYQ_JboA
yes,,my wife is only 32,, recently detected with stage 4 fallopian tube cancer.she was almost fine just befor the ascities in her abdomen.In bangladesh its hard to early diagnosis.
The FDA has granted accelerated approval to mirvetuximab soravtansine (Elahere) for use in pretreated patients with folate receptor (FR) alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, and primary peritoneal cancer. These patients can have received one to three prior lines of treatment. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. "Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial," according to labeling. Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) with an antibody directed against FR alpha that is linked to a microtubule inhibitor conjugate. This product is a first-in-class ADC directed against FR alpha, a cell-surface protein highly expressed in ovarian cancer, and is the first FDA-approved ADC for platinum-resistant disease, said the manufacturer, ImmunoGen. Patients are selected for treatment with this drug using a diagnostic test that the FDA approved along with the agent: the VENTANA FOLR1 (FOLR-2.1) RxDx Assay.
NCCN guidelines for Ovarian Cancer 2022 Treatment options for elderly patients (age >70 years) and/or those with comorbidities are as follows: * Intravenous (IV) paclitaxel, 135 mg/m2 plus IV carboplatin, area under the curve (AUC) 5 given every 21 days for 3 to 6 cycles, depending on stage and cancer subtype * IV paclitaxel, 60 mg/m2, followed by intravenous carboplatin, AUC 2 on days 1, 8, and 15, repeated every 21 days for 6 cycles The latter option can also be considered for patients with poor performance status. Single-agent carboplatin is no longer recommended for this patient population. ----- Low-grade serous carcinoma (LGSC) In patients with low-grade serous carcinoma (LGSC), recommendations for adjuvant treatment are stratified by stage, as follows: * Stage IA and IB - Postoperative observation * Stage IC or stage II-IV - Several adjuvant systemic therapy options are recommended, including paclitaxel/platinum-containing regimens Patients with LGSC may also benefit from maintenance hormone therapy following adjuvant chemotherapy. Patients with LGSC should be monitored for potential recurrence through follow-up visits every 2 to 4 months for 2 years, followed by 3 to 6 months for 3 years, and then annually after 5 years. Monitoring should consist of a physical examination, including a pelvic examination; tumor molecular testing, if not previously done; and imaging and complete blood cell count/chemistry profile. Treatment options for patients with recurrent LGSC are as follows: * Secondary cytoreduction can be considered for patients with a long disease-free interval, isolated masses rather than diffuse carcinomatosis on imaging, and/or bowel obstruction. * Recommended systemic therapies include chemotherapy (if not previously used) and hormonal therapy. However, there is no standard sequencing of drugs for recurrent disease, so patients should be evaluated on an individual basis. Options include the MEK inhibitors trametinib and binimetinib and, for patients with a BRAF V600E mutation, dabrafenib plus trametinib. In patients with ovarian, fallopian tube, or primary peritoneal cancers, tumor testing for select biomarkers is recommended in the up-front and recurrence settings, to identify molecular alterations that can inform the use of interventions such as PARP inhibitors. Biomarker testing should include BRCA1/2 status, loss of heterozygosity, or (in the absence of a germline BRCA mutation) homologous recombination status.
Every woman should be tested for Brca genes (1 or 2) at an early age and when deciding to be finished with child bearing should have fallopian tube removal or better yet complete hysterectomy to prevent any chance of ovarian cancer which is found in MANY of cases is a death sentence. Gynecologists should be more assertive and informative with their patients.
Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20. Methods: Pts with ROC and 1st relapse after 6+ months (mos) platinum-free interval (TFIp) were eligible if they presented with a positive AGO-score (PS ECOG 0, ascites ≤500 ml, and complete resection at initial surgery) and were prospectively randomized to second-line chemotherapy alone vs. cytoreductive surgery followed by the same chemotherapy; platinum combination therapy was recommended. Results: 407pts were randomized 2010-2014. The TFIp exceeded 12 mos in 75% of pts. 206 pts were allocated to the surgery arm of whom finally 187 (91%) were operated. A complete resection was achieved in 75%; almost 90% in both arms received a platinum-containing second-line chemo. Primary endpoint analysis showed median OS of 53.7 mos with and 46.2 mos without surgery (HR 0.76, 95%CI 0.59-0.97, p=0.03); median PFS was 18.4 and 14 mos (HR: 0.66, 95%CI 0.54-0.82, p
Bonjour, est-ce que l'olaparib est plus efficace en association avec des compléments alimentaires comme la vitamine C liposomal ? Je reçois de l'olaparib et du beva Merci
my wife got clear cell at 1c stage but she got fully surgery and 6 round of chemotherapy , now it's 6 months , I wish the survivor rate more than 5year is more , even it's clear cell , how could I recommend my wife for eating , vitamin , or any recommendation , she just only 46 years old , I wish she would stay with me longer as possible.
@@monicag6715 Thanks , really appreciated your kind answer. Today we just to have regular checking & CA125 result at 9months period after final round of chemotherapy , the figure looks good CA125 is around 8.90 , and it keep this rate since 3 months, 6 months cycle. (8.90-9.30) . now we changed most of eating habits / IF / more activity to keep physical good / less sugar / many many things changed. I hope we could live more longer as much possible , Thanks Monica .
For recurrent low grade serous carcinoma, trametinib, a MEK inhibitor, improved PF-survival, and will be the standard of care. pubmed.ncbi.nlm.nih.gov/35123694/
Such a great Presentation and explanation Dr Kim, I wish all patients survived and recovered from this disease.
My mom died of Ovarian cancer over 20 years ago. By the time it was detected, she was already at stage 3 or 4. It's sad that in 2021 there is still no effective way to detect this cancer earlier and therefore increase the likelihood of survival.
I have be dealing with Cancer disease for the past years until i got review online about Dr.Auchi on RUclips Channel people testifies how they got cured with his herbal medicine, I order the treatment and after taking it for few weeks i totally got cured permanently ruclips.net/channel/UCz9T50vxGu2pQMiJYQ_JboA
yes,,my wife is only 32,, recently detected with stage 4 fallopian tube cancer.she was almost fine just befor the ascities in her abdomen.In bangladesh its hard to early diagnosis.
The FDA has granted accelerated approval to mirvetuximab soravtansine (Elahere) for use in pretreated patients with folate receptor (FR) alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, and primary peritoneal cancer. These patients can have received one to three prior lines of treatment.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
"Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial," according to labeling.
Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) with an antibody directed against FR alpha that is linked to a microtubule inhibitor conjugate.
This product is a first-in-class ADC directed against FR alpha, a cell-surface protein highly expressed in ovarian cancer, and is the first FDA-approved ADC for platinum-resistant disease, said the manufacturer, ImmunoGen.
Patients are selected for treatment with this drug using a diagnostic test that the FDA approved along with the agent: the VENTANA FOLR1 (FOLR-2.1) RxDx Assay.
NCCN guidelines for Ovarian Cancer 2022
Treatment options for elderly patients (age >70 years) and/or those with comorbidities are as follows:
* Intravenous (IV) paclitaxel, 135 mg/m2 plus IV carboplatin, area under the curve (AUC) 5 given every 21 days for 3 to 6 cycles, depending on stage and cancer subtype
* IV paclitaxel, 60 mg/m2, followed by intravenous carboplatin, AUC 2 on days 1, 8, and 15, repeated every 21 days for 6 cycles
The latter option can also be considered for patients with poor performance status. Single-agent carboplatin is no longer recommended for this patient population.
-----
Low-grade serous carcinoma (LGSC)
In patients with low-grade serous carcinoma (LGSC), recommendations for adjuvant treatment are stratified by stage, as follows:
* Stage IA and IB - Postoperative observation
* Stage IC or stage II-IV - Several adjuvant systemic therapy options are recommended, including paclitaxel/platinum-containing regimens
Patients with LGSC may also benefit from maintenance hormone therapy following adjuvant chemotherapy.
Patients with LGSC should be monitored for potential recurrence through follow-up visits every 2 to 4 months for 2 years, followed by 3 to 6 months for 3 years, and then annually after 5 years. Monitoring should consist of a physical examination, including a pelvic examination; tumor molecular testing, if not previously done; and imaging and complete blood cell count/chemistry profile.
Treatment options for patients with recurrent LGSC are as follows:
* Secondary cytoreduction can be considered for patients with a long disease-free interval, isolated masses rather than diffuse carcinomatosis on imaging, and/or bowel obstruction.
* Recommended systemic therapies include chemotherapy (if not previously used) and hormonal therapy. However, there is no standard sequencing of drugs for recurrent disease, so patients should be evaluated on an individual basis. Options include the MEK inhibitors trametinib and binimetinib and, for patients with a BRAF V600E mutation, dabrafenib plus trametinib.
In patients with ovarian, fallopian tube, or primary peritoneal cancers, tumor testing for select biomarkers is recommended in the up-front and recurrence settings, to identify molecular alterations that can inform the use of interventions such as PARP inhibitors. Biomarker testing should include BRCA1/2 status, loss of heterozygosity, or (in the absence of a germline BRCA mutation) homologous recombination status.
Every woman should be tested for Brca genes (1 or 2) at an early age and when deciding to be finished with child bearing should have fallopian tube removal or better yet complete hysterectomy to prevent any chance of ovarian cancer which is found in MANY of cases is a death sentence. Gynecologists should be more assertive and informative with their patients.
Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.
Methods: Pts with ROC and 1st relapse after 6+ months (mos) platinum-free interval (TFIp) were eligible if they presented with a positive AGO-score (PS ECOG 0, ascites ≤500 ml, and complete resection at initial surgery) and were prospectively randomized to second-line chemotherapy alone vs. cytoreductive surgery followed by the same chemotherapy; platinum combination therapy was recommended.
Results: 407pts were randomized 2010-2014. The TFIp exceeded 12 mos in 75% of pts. 206 pts were allocated to the surgery arm of whom finally 187 (91%) were operated. A complete resection was achieved in 75%; almost 90% in both arms received a platinum-containing second-line chemo. Primary endpoint analysis showed median OS of 53.7 mos with and 46.2 mos without surgery (HR 0.76, 95%CI 0.59-0.97, p=0.03); median PFS was 18.4 and 14 mos (HR: 0.66, 95%CI 0.54-0.82, p
잘 배우고 갑니다! 감사합니다 선생님
Bonjour, est-ce que l'olaparib est plus efficace en association avec des compléments alimentaires comme la vitamine C liposomal ? Je reçois de l'olaparib et du beva
Merci
my wife got clear cell at 1c stage but she got fully surgery and 6 round of chemotherapy , now it's 6 months , I wish the survivor rate more than 5year is more , even it's clear cell , how could I recommend my wife for eating , vitamin , or any recommendation , she just only 46 years old , I wish she would stay with me longer as possible.
I think her survival rate is 92% so don’t worry.
@@monicag6715 Thanks , really appreciated your kind answer. Today we just to have regular checking & CA125 result at 9months period after final round of chemotherapy , the figure looks good CA125 is around 8.90 , and it keep this rate since 3 months, 6 months cycle. (8.90-9.30) . now we changed most of eating habits / IF / more activity to keep physical good / less sugar / many many things changed. I hope we could live more longer as much possible , Thanks Monica .
Keep her happy as the caring husband you are.
my wife has ovarian cancer 3c too ... thaks 4 share
@@richyneung
What's the update brother?
CARBOPLATIN can be made without Taxol?
Which is treatment for ovarian cancer stage 3 c
20:33
Can i ask something. .?
For recurrent low grade serous carcinoma, trametinib, a MEK inhibitor, improved PF-survival, and will be the standard of care.
pubmed.ncbi.nlm.nih.gov/35123694/
These toxic chemo drugs have been used for the last 45 years or more.